A Prospective Observational Validation Study of the A&M Breathalyzer PROTECT Kiosk for COVID-19 Detection in Military Operational Medicine

What this Trial Is About

This research aims to optimize and validate innovative passive surveillance systems for detecting COVID-19 and other respiratory diseases in military environments. The study focuses on assessing new diagnostic technologies, specifically the A&M Breathalyzer PROTECT Kiosk, to improve rapid and non-invasive detection of COVID-19 among both symptomatic and asymptomatic individuals. The goal is to enhance military operational readiness by reducing the impact of acute respiratory diseases through better screening methods. The A&M Breathalyzer PROTECT Kiosk, a portable mass spectrometer device, will be tested and modified at Brooke Army Medical Center. It collects breath samples passively without the need for direct breath collection, using sensors analyzed by an integrated AI platform to detect SARS-CoV-2 components. The study includes participants with known positive or negative COVID-19, Flu, or RSV test results obtained within 48 hours of recruitment, comparing breathalyzer results to standard RT-PCR tests. Participants will undergo breath capture sampling and temperature thermal scans, with data collected over a period from at least 48 hours up to 12 months. Researchers will monitor the device’s detection accuracy, sensor performance, and data analyzed by the AI system. The study involves observational monitoring without intervention, aiming to validate the breathalyzer's capability for passive detection in real-world clinical settings to support operational medicine.

Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine